2012

Doores, K. J., Huber, M., Le, K. M., Wang, S. K., Doyle-Cooper, C., Cooper, A., Pantophlet, R., Wong, C. H., Nemazee, D. and Burton, D. R. 2012. 2G12-expressing B cell lines inform HIV carbohydrate vaccine design strategies. J. Virol. 87:2234-2241.

Benhnia, M. R., Maybeno, M., Blum, D., Aguilar-Sino, R., Matho, M., Meng, X., Head, S., Felgner, P. L., Zajonc, D. M., Koriazova, L., Kato, S., Burton, D. R., Xiang, Y., Crowe, J. E. Jr, Peters, B., and Crotty, S. 2012. Unusual features of vaccinia virus extracellular virion form (EV) neutralization resistance revealed in human antibody responses to the smallpox vaccine. J Virol. 87:1569-1585.

Hoot, S., McGuire, A. T., Cohen, K. W., Strong, R. K., Hangartner, L., Klein, F., Diskin, R., Scheid, J. F., Sather, D. N., Burton, D. R. and Stamatatos, L. 2013. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog 9:e1003106.

Moldt, B., Rakasz, E. G., Schultz, N., Chan-Hui, P. Y., Swiderek, K., Weisgrau, K. L., Piaskowski, S. M., Bergman, Z., Watkins, D. I., Poignard, P., Burton, D. R. 2012. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A. 109:18921-18925.

Ota, T., Doyle-Cooper, C., Cooper, A. B., Huber, M., Falkowska, E., Doores, K. J., Hangartner, L., Le, K., Sok, D., Jardine, J., Lifson, J., Wu, X., Mascola, J. R., Poignard, P., Binley, J. M., Chakrabarti, B. K., Schief, W. R., Wyatt, R. T., Burton, D. R., and Nemazee, D. 2012. Anti-HIV B Cell Lines as Candidate Vaccine Biosensors. J Immunol. 189:4816-4824.

Burton, D. R., Ahmed, R., Barouch, D. H., Butera, S. T., Crotty, S., Godzik, A., Kaufmann, D. E., McElrath, M. J., Nussenzweig, M. C., Pulendran, B., Scanlan, C. N., Schief, W. R., Silvestri, G., Streeck, H., Walker, B. D., Walker, L. M., Ward, A. B., Wilson, I. A., and Wyatt, R. 2012. A Blueprint for HIV Vaccine Discovery. Cell Host Microbe. 12:396-407.

Zhu, Z., S. O’Dell, G. Ofek, M. Pancera, X. Wu, B. Zhang, Z. Zhang, J. C. Mullikan, M. D. Simek, D. R. Burton, and et al. 2012. Somatic populations of PGT135-137 HIV-1-neutralizing antibodies identified by 454 pyrosequencing and bioinformatics. Front Microbiol. 3:315.

Burton, D. R., P. Poignard, R. L. Stanfield, and I. A. Wilson. 2012. Broadly neutralizing antibodies: new prospects to counter highly antigenically diverse viruses. Science 337:183-186.

Doria-Rose, N. A., I. Georgiev, S. O’Dell, G. Y. Chuang, R. P. Staupe, J. S. McLellan, J. Gorman, M. Pancera, M. Bonsignori, B. F. Haynes, D. R. Burton, W. C. Koff, P. D. Kwong, and J. R. Mascola. 2012. A Short Segment of the HIV-1 gp120 V1/V2 Region Is a Major Determinant of Resistance to V1/V2 Neutralizing Antibodies. J. Virol. 86:8319-8323.

Falkowska, E., A. Ramos, Y. Feng, T. Zhou, S. Moquin, L. M. Walker, X. Wu, M. S. Seaman, T. Wrin, P. D. Kwong, R. T. Wyatt, J. R. Mascola, P. Poignard, and D. R. Burton. 2012. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J. Virol. 86:4394-4403.

Giang, E., M. Dorner, J. C. Prentoe, M. Dreux, M. J. Evans, J. Bukh, C. M. Rice, A. Ploss, D. R. Burton, and M. Law. 2012. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 109:6205-6210.

Kong, L., E. Giang, J. B. Robbins, R. L. Stanfield, D. R. Burton, I. A. Wilson, and M. Law. 2012. Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc. Natl. Acad. Sci. U. S. A. 109:9499-9504.

Moldt, B., M. Shibata-Koyama, E. G. Rakasz, N. Schultz, Y. Kanda, D. C. Dunlop, S. L. Finstad, C. Jin, G. Landucci, M. D. Alpert, A. S. Dugast, P. W. Parren, F. Nimmerjahn, D. T. Evans, G. Alter, D. N. Forthal, J. E. Schmitz, S. Iida, P. Poignard, D. I. Watkins, A. J. Hessell, and D. R. Burton. 2012. A Nonfucosylated Variant of the anti-HIV-1 Monoclonal Antibody b12 Has Enhanced FcgammaRIIIa-Mediated Antiviral Activity In Vitro but Does Not Improve Protection against Mucosal SHIV Challenge in Macaques. J. Virol. 86:6189-6196.

Montero, M., N. Gulzar, K. A. Klaric, J. E. Donald, C. Lepik, S. Wu, S. Tsai, J. P. Julien, A. J. Hessell, S. Wang, S. Lu, D. R. Burton, E. F. Pai, W. F. Degrado, and J. K. Scott. 2012. Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane. J. Virol. 86:2930-2941.

Poignard, P., B. Moldt, K. Maloveste, N. Campos, W. C. Olson, E. Rakasz, D. I. Watkins, and D. R. Burton. 2012. Protection against High-Dose Highly Pathogenic Mucosal SIV Challenge at Very Low Serum Neutralizing Titers of the Antibody-Like Molecule CD4-IgG2. Plos One 7:e42209.

Ahmed, F. K., B. E. Clark, D. R. Burton, and R. Pantophlet. 2012. An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site. Vaccine 30:922-930.